Elanco Animal Health (Elanco Animal Health) Cash And Cash Equivalents : $352 Mil (As of Dec. 2023)

View and export this data going back to 2018. Start your Free Trial

What is Elanco Animal Health Cash And Cash Equivalents?

Elanco Animal Health's quarterly cash and cash equivalents increased from Jun. 2023 ($367.00 Mil) to Sep. 2023 ($369.00 Mil) but then stayed the same from Sep. 2023 ($369.00 Mil) to Dec. 2023 ($352.00 Mil).

Elanco Animal Health's annual cash and cash equivalents declined from Dec. 2021 ($638.00 Mil) to Dec. 2022 ($345.00 Mil) but then increased from Dec. 2022 ($345.00 Mil) to Dec. 2023 ($352.00 Mil).

Elanco Animal Health Cash And Cash Equivalents Historical Data

The historical data trend for Elanco Animal Health's Cash And Cash Equivalents can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Elanco Animal Health Cash And Cash Equivalents Chart

Elanco Animal Health Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash And Cash Equivalents

Get a 7-Day Free Trial

334.00

495.00

638.00

345.00

352.00

Elanco Animal Health Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Cash And Cash Equivalents	Get a 7-Day Free Trial															345.00	318.00	367.00	369.00	352.00

Elanco Animal Health Cash And Cash Equivalents Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Elanco Animal Health (NYSE:ELAN) Cash And Cash Equivalents Explanation

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Be Aware

Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.

Elanco Animal Health Cash And Cash Equivalents Related Terms

Thank you for viewing the detailed overview of Elanco Animal Health's Cash And Cash Equivalents provided by GuruFocus.com. Please click on the following links to see related term pages.

Elanco Animal Health (Elanco Animal Health) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Elanco Animal Health Inc (NYSE:ELAN) » Definitions » Cash And Cash Equivalents

Comparable Companies

Traded in Other Exchanges

5EA:Germany

Address

2500 Innovation Way, Greenfield, IN, USA, 46140

Website

https://www.elanco.com

Elanco Animal Health Inc is an animal health company that is engaged in innovating, developing, manufacturing, and marketing products for companion and food animals. Geographically, the company's operations are conducted globally and sell its products in over 90 countries. It offers a range of food animal products used in cattle, sheep, goats, and swine production.

Executives

Grace Mcardle	officer: EVP, MANUFACTURING AND QUALITY	2500 INNOVATION WAY, GREENFIELD IN 46140
Timothy J Bettington	officer: See remarks	C/O ZOETIS INC., 10 SYLVAN WAY, PARSIPPANY NJ 07054
R David Hoover	director	C/O EDGEWELL PERSONAL CARE COMPANY, 1350 TIMBERLAKE MANOR PARKWAY, CHESTERFIELD MO 63017
Jeffrey N Simmons	director, officer: Pres., Chief Executive Officer	2500 INNOVATION WAY, GREENFIELD IN 46140
John P Bilbrey	director
Rajeev A. Modi	officer: See Remarks	2500 INNOVATION WAY, GREENFIELD IN 46140
Paul Herendeen	director	C/O BAUSCH HEALTH COMPANIES INC., 400 SOMERSET CORPORATE BLVD., BRIDGEWATER NJ 08807
Michael J Harrington	director	LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285
Brabander Ellen De	officer: See Remarks	2500 INNOVATION WAY, GREENFIELD IN 46140
Marcela A. Kirberger	officer: Ex VP, Gen Counsel & Corp Sec	C/O ELANCO ANIMAL HEALTH INCORPORATED, 2500 INNOVATION WAY, GREENFIELD IN 46140
Art A Garcia	director	11690 N.W. 105TH STREET, MIAMI FL 33178
William F Doyle	director
Uncas Gp Llc	director	250 WEST 55TH STREET, 34TH FLOOR, NEW YORK NY 10019
Sachem Head Capital Management Lp	director	250 WEST 55TH STREET, 34TH FLOOR, NEW YORK NY 10019
Scott D. Ferguson	director	250 WEST 55TH STREET, 34TH FLOOR, NEW YORK NY 10019